RecruitingPhase 4

Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia

Australia300 participantsStarted 2024-11-14

Plain-language summary

This is an open label randomized controlled trial for patients with methicillin resistant S. aureus (MRSA) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin. This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

The participant must meet all inclusion and exclusion criteria for the SNAP Platform (NCT05137119) and also the following inclusion and exclusion criteria: Inclusion Criteria: * Methicillin-resistant S. aureus bacteremia Exclusion Criteria: * Severe allergy or non-severe rash to vancomycin or daptomycin * Suspected or confirmed MRSA pneumonia * Known vancomycin minimum inhibitory concentration (MIC) greater than or equal to 2mg/L or daptomycin MIC greater than or equal to 1mg/L

What they're measuring

Desirability of Outcome Ranking (DOOR)

Timeframe: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

Trial details

NCT IDNCT06637332

SponsorTodd C. Lee MD MPH FIDSA

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-01

Contact for this trial

Lina Petrella

514-934-1934 lina.petrella@muhc.mcgill.ca

View on ClinicalTrials.gov More Staphylococcus Aureus Septicemia trials